<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2011//EN" "http://www.ncbi.nlm.nih.gov/entrez/query/DTD/pubmed_110101.dtd">
<pubmedarticleset>
 <pubmedarticle>
  <medlinecitation owner="NLM" status="MEDLINE">
   <pmid version="1">
    15316107
   </pmid>
   <datecreated>
    <year>
     2004
    </year>
    <month>
     09
    </month>
    <day>
     17
    </day>
   </datecreated>
   <datecompleted>
    <year>
     2004
    </year>
    <month>
     12
    </month>
    <day>
     22
    </day>
   </datecompleted>
   <daterevised>
    <year>
     2010
    </year>
    <month>
     11
    </month>
    <day>
     18
    </day>
   </daterevised>
   <article pubmodel="Print-Electronic">
    <journal>
     <issn issntype="Print">
      1060-0280
     </issn>
     <journalissue citedmedium="Print">
      <volume>
       38
      </volume>
      <issue>
       10
      </issue>
      <pubdate>
       <year>
        2004
       </year>
       <month>
        Oct
       </month>
      </pubdate>
     </journalissue>
     <title>
      The Annals of pharmacotherapy
     </title>
     <isoabbreviation>
      Ann Pharmacother
     </isoabbreviation>
    </journal>
    <articletitle>
     Treatment of migraine headaches with sumatriptan in pregnancy.
    </articletitle>
    <pagination>
     <medlinepgn>
      1726-30
     </medlinepgn>
    </pagination>
    <abstract>
     <abstracttext label="OBJECTIVE" nlmcategory="OBJECTIVE">
      To review the literature for treatment of migraine headaches with sumatriptan during pregnancy.
     </abstracttext>
     <abstracttext label="DATA SOURCES" nlmcategory="METHODS">
      Studies and reports were located in International Pharmaceutical Abstracts (1970-September 2003) and MEDLINE (1966-week 3 September 2003).
     </abstracttext>
     <abstracttext label="DATA SYNTHESIS" nlmcategory="RESULTS">
      Research has been performed to evaluate the risk of teratogenesis after sumatriptan exposure in pregnant patients. Data have been collected in areas including placental transmission of sumatriptan, prospective pregnancy registries, open-labeled and controlled prospective studies, and a retrospective prescription-linked study. As of August 6, 2004, no randomized controlled trials have been conducted with exposure to sumatriptan during pregnancy.
     </abstracttext>
     <abstracttext label="CONCLUSIONS" nlmcategory="CONCLUSIONS">
      Teratogenesis occurs in approximately 150 000 births per year which represents an incidence of 3-5%. Available literature to date indicates that exposure to sumatriptan during pregnancy has no additional risk of birth defects compared with the incidence in the general population.
     </abstracttext>
    </abstract>
    <affiliation>
     University of Tennessee Family Practice Center, Memphis, TN, USA. mhilaire@utmem.edu
    </affiliation>
    <authorlist completeyn="Y">
     <author validyn="Y">
      <lastname>
       Hilaire
      </lastname>
      <forename>
       Michelle L
      </forename>
      <initials>
       ML
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Cross
      </lastname>
      <forename>
       L Brian
      </forename>
      <initials>
       LB
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Eichner
      </lastname>
      <forename>
       Samantha F
      </forename>
      <initials>
       SF
      </initials>
     </author>
    </authorlist>
    <language>
     eng
    </language>
    <publicationtypelist>
     <publicationtype>
      Journal Article
     </publicationtype>
     <publicationtype>
      Review
     </publicationtype>
    </publicationtypelist>
    <articledate datetype="Electronic">
     <year>
      2004
     </year>
     <month>
      08
     </month>
     <day>
      17
     </day>
    </articledate>
   </article>
   <medlinejournalinfo>
    <country>
     United States
    </country>
    <medlineta>
     Ann Pharmacother
    </medlineta>
    <nlmuniqueid>
     9203131
    </nlmuniqueid>
    <issnlinking>
     1060-0280
    </issnlinking>
   </medlinejournalinfo>
   <chemicallist>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Serotonin Receptor Agonists
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      103628-46-2
     </registrynumber>
     <nameofsubstance>
      Sumatriptan
     </nameofsubstance>
    </chemical>
   </chemicallist>
   <citationsubset>
    IM
   </citationsubset>
   <meshheadinglist>
    <meshheading>
     <descriptorname majortopicyn="N">
      Abnormalities, Drug-Induced
     </descriptorname>
     <qualifiername majortopicyn="N">
      etiology
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Clinical Trials as Topic
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Female
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Humans
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Migraine Disorders
     </descriptorname>
     <qualifiername majortopicyn="Y">
      drug therapy
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Pregnancy
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Pregnancy Complications, Cardiovascular
     </descriptorname>
     <qualifiername majortopicyn="Y">
      drug therapy
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Pregnancy Outcome
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Risk Factors
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Serotonin Receptor Agonists
     </descriptorname>
     <qualifiername majortopicyn="Y">
      adverse effects
     </qualifiername>
     <qualifiername majortopicyn="N">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Sumatriptan
     </descriptorname>
     <qualifiername majortopicyn="Y">
      adverse effects
     </qualifiername>
     <qualifiername majortopicyn="N">
      therapeutic use
     </qualifiername>
    </meshheading>
   </meshheadinglist>
   <numberofreferences>
    20
   </numberofreferences>
  </medlinecitation>
  <pubmeddata>
   <history>
    <pubmedpubdate pubstatus="pubmed">
     <year>
      2004
     </year>
     <month>
      8
     </month>
     <day>
      19
     </day>
     <hour>
      5
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="medline">
     <year>
      2004
     </year>
     <month>
      12
     </month>
     <day>
      23
     </day>
     <hour>
      9
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="aheadofprint">
     <year>
      2004
     </year>
     <month>
      Aug
     </month>
     <day>
      17
     </day>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="entrez">
     <year>
      2004
     </year>
     <month>
      8
     </month>
     <day>
      19
     </day>
     <hour>
      5
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
   </history>
   <publicationstatus>
    ppublish
   </publicationstatus>
   <articleidlist>
    <articleid idtype="pubmed">
     15316107
    </articleid>
    <articleid idtype="doi">
     10.1345/aph.1D586
    </articleid>
    <articleid idtype="pii">
     aph.1D586
    </articleid>
   </articleidlist>
  </pubmeddata>
 </pubmedarticle>
</pubmedarticleset>

